Fusion Antibodies PLC
LSE:FAB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Fusion Antibodies PLC
Cash & Cash Equivalents
Fusion Antibodies PLC
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Fusion Antibodies PLC
LSE:FAB
|
Cash & Cash Equivalents
£252k
|
CAGR 3-Years
-41%
|
CAGR 5-Years
-40%
|
CAGR 10-Years
N/A
|
|
|
Oxford Biodynamics PLC
LSE:OBD
|
Cash & Cash Equivalents
£1.4m
|
CAGR 3-Years
13%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
N/A
|
|
|
Oxford Nanopore Technologies PLC
LSE:ONT
|
Cash & Cash Equivalents
£181.1m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
|
Diaceutics PLC
LSE:DXRX
|
Cash & Cash Equivalents
£12.7m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
|
G
|
Genedrive PLC
LSE:GDR
|
Cash & Cash Equivalents
£387k
|
CAGR 3-Years
-43%
|
CAGR 5-Years
-37%
|
CAGR 10-Years
-16%
|
|
|
hVIVO PLC
LSE:HVO
|
Cash & Cash Equivalents
£14.3m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
18%
|
|
Fusion Antibodies PLC
Glance View
Fusion Antibodies Plc engages in the provision of antibody engineering services for all stages of therapeutic and diagnostic antibody development. The company is headquartered in Belfast, Northern Ireland and currently employs 54 full-time employees. The company went IPO on 2017-12-18. The firm offers a range of antibody engineering services for all stages of therapeutic and diagnostic antibody development. The principal activity of the Company is the research, development and manufacture of recombinant proteins and antibodies, particularly in the areas of cancer and infectious diseases. The Company’s services include discovery, engineering and supply. Discovery services includes creation, screening and sequencing of monoclonal antibodies for therapeutic and diagnostic applications. Engineering services includes maximizing the performance of an antibody drug including CDRx humanization, Antibody Developability by Design (ADDTM) and RAMP. Supply services includes the production of material for clinical production or further research, including cGMP ready stable cell line development and transient expression.
See Also
What is Fusion Antibodies PLC's Cash & Cash Equivalents?
Cash & Cash Equivalents
252k
GBP
Based on the financial report for Sep 30, 2025, Fusion Antibodies PLC's Cash & Cash Equivalents amounts to 252k GBP.
What is Fusion Antibodies PLC's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
-40%
Over the last year, the Cash & Cash Equivalents growth was -43%. The average annual Cash & Cash Equivalents growth rates for Fusion Antibodies PLC have been -41% over the past three years , -40% over the past five years .
